Hematologic responses
| Regime . | n . | ORR (ITT) . | CR (ITT) . | PR (ITT) . | ORR (evaluable) . |
|---|---|---|---|---|---|
| MDex | 154 | 40% | 15% | 25% | 60% |
| Thalidomide combination | 96 | 32% | 11% | 21% | 64% |
| Bortezomib combination | 23 | 43% | 26% | 13% | 62% |
| Lenalidomide combination | 13 | 38% | 0% | 38% | 41% |
| Regime . | n . | ORR (ITT) . | CR (ITT) . | PR (ITT) . | ORR (evaluable) . |
|---|---|---|---|---|---|
| MDex | 154 | 40% | 15% | 25% | 60% |
| Thalidomide combination | 96 | 32% | 11% | 21% | 64% |
| Bortezomib combination | 23 | 43% | 26% | 13% | 62% |
| Lenalidomide combination | 13 | 38% | 0% | 38% | 41% |
ORR, overall response rate.